Claudia Solich Email

Safety Officer ; Senior Qualification Engineer . Dynavax Technologies

Current Roles

Employees:
423
Revenue:
$91.8M
About
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company?s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development.
Dynavax Technologies Address
2100 Powell Street
null, null
Dynavax Technologies Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.